Therapeutic uses of PSMA targeted bispecific polypeptides

The conditionally-activatable PSMA-XPAT T Cell Engager addresses on-target toxicities and CRS by activating only in the tumor microenvironment, providing effective and safe treatment for prostate cancer with minimal side effects.

WO2026136926A1PCT designated stage Publication Date: 2026-06-25VIR BIOTECHNOLOGY INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
VIR BIOTECHNOLOGY INC
Filing Date
2025-12-19
Publication Date
2026-06-25

Smart Images

  • Figure IMGF000032_0001
    Figure IMGF000032_0001
  • Figure IMGF000032_0002
    Figure IMGF000032_0002
  • Figure IMGF000033_0001
    Figure IMGF000033_0001
Patent Text Reader

Abstract

Provided are compositions and methods for treating cancers, in particular those characterized with PSMA expression such as prostate cancer. The compositions include a conditionally-activatable XTENylated Protease-Activated bispecific T Cell Engager targeting PSMA (PSMA-XPAT) that remain inactive until activated by proteases present in tumor microenvironment. The PSMA-XPAT exhibited exceptional safety profiles even at high doses and were efficacious in cancer patients resistant to even multiple lines of prior therapies.
Need to check novelty before this filing date? Find Prior Art